Provided By GlobeNewswire
Last update: Feb 14, 2024
WARREN, N.J., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen Bio”), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology, has announced the completion of Tevogen Bio Inc’s previously announced business combination with Semper Paratus Acquisition Corporation, leading to the formation of Tevogen Bio Holdings Inc. The combined company’s common stock and warrants will begin trading on Nasdaq Global Market (“Nasdaq”) under the ticker symbols TVGN and TVGNW, respectively, beginning Thursday, February 15, 2024.
Read more at globenewswire.com